UNSPSC 51433801: Cadralazine

This classification denotes an antihypertensive agent with the molecular formula C12H21N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8T96I3U713, chemically known as hydrazinecarboxylic acid, 2-(6-(ethyl(2-hydroxypropyl)amino)-3-pyridazinyl)-, ethyl ester but generally known as cadralazine, which bears US NIH Compound Identifier 2515. European Medicines Agency schedules Cadralazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06042MIG.

UNSPSC 51433801 Cadralazine, a Commodity code, covers emergency and critical-care medications supplied to state and local health agencies, fire departments, and hospital systems. Recent solicitations under this code show state and local governments procuring advanced life support medications—including specific injectable drugs like labetalol, epinephrine, adenosine, and diltiazem—for emergency medical services and pharmacy benefit programs. The issuing bodies span municipal fire rescue departments, state health agencies, and multistate cooperative purchasing alliances. The City of Tampa's fire rescue department and the Texas Health and Human Services Commission represent the primary recent buyers, though the scope also includes institutional pharmacy procurement through cooperative contracts serving multiple state and local jurisdictions. Work being solicited ranges from direct supply of injectable medications with strict expiration and warranty requirements to strategic sourcing arrangements for generic pharmaceuticals and OTC products distributed through authorized wholesalers.

Activity appears concentrated in Florida and Texas, with broader multistate reach through cooperative purchasing mechanisms. The City of Tampa issued an IFB (Bid No. 26-P-00188) on April 24, 2026, seeking 370 units of labetalol HCI 100mg vials, 1,810 units of epinephrine 1:10,000 injections, 330 units of adenosine 6mg vials, and 1,020 units of diltiazem 25mg vials for Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00; the contract carries a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802) with a March 26, 2026 deadline for generic multi-source pharmaceuticals and OTC products available through three authorized wholesalers (Cencora, Cardinal Health, and Morris & Dickson), with awards effective July 1, 2026 and a two-year initial term. The Texas HHS Commission issued an RFI (HHS0017013) in March 2026 to gather market intelligence on direct-to-manufacturer prescription programs, indicating early-stage planning for pharmacy benefit expansion but not a formal solicitation with award value or timeline.